Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 7/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | XPO1 | O14980 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | ADH5 | P11766 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365510 | 0.88 | SRD5A2 (0.41) | RXRARXRBRXRGSRD5A2SRD5A1 | |
| SCHEMBL12389665 | 0.86 | NOTUM (0.43) | CES2MAPK14 | |
| SCHEMBL12389569 | 0.85 | SRD5A2 (0.46) | RXRARXRBRXRGSRD5A2SRD5A1 | |
| SCHEMBL12390230 | 0.85 | SLC9A1 (0.43) | — | |
| SCHEMBL12388304 | 0.84 | EPHX2 (0.42) | SRD5A2MAPK14 | |
| SCHEMBL12390197 | 0.84 | RARA (0.49) | RXRARXRBRXRGSRD5A2SRD5A1 | |
| SCHEMBL12389766 | 0.81 | IP6K1 (0.46) | RXRARXRBRXRGSRD5A2CES2 | |
| SCHEMBL12389667 | 0.78 | RXRA (0.40) | RXRARXRBRXRGSRD5A2CES2 | |
| SCHEMBL12365499 | 0.76 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL12365397 | 0.75 | SRD5A2 (0.41) | SRD5A2SRD5A1TTRALDH1A1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | RXRA 2978/4885RXRB 3078/4885RXRG 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.